Treatment possibilities for psychosis in Parkinson’s disease with an emphasis on the newly approved drug: Pimavanserin

Zsófia Majláth, Izabella Obál, L. Vécsei

Research output: Contribution to journalReview article

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2A) triggered mechanisms. A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist.

Original languageEnglish
Pages (from-to)234-243
Number of pages10
JournalCNS and Neurological Disorders - Drug Targets
Volume16
Issue number3
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Psychotic Disorders
Parkinson Disease
Serotonin 5-HT2 Receptor Agonists
Antipsychotic Agents
Clozapine
Pharmaceutical Preparations
Receptor, Serotonin, 5-HT2A
Delusions
Hallucinations
Therapeutics
Neurodegenerative Diseases
Caregivers
Pimavanserin
Research
Quetiapine Fumarate

Keywords

  • Clozapine
  • Parkinson’s disease psychosis
  • Pimavanserin
  • Quetiapine
  • Serotonin 2a receptor inverse agonist

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Treatment possibilities for psychosis in Parkinson’s disease with an emphasis on the newly approved drug : Pimavanserin. / Majláth, Zsófia; Obál, Izabella; Vécsei, L.

In: CNS and Neurological Disorders - Drug Targets, Vol. 16, No. 3, 01.01.2017, p. 234-243.

Research output: Contribution to journalReview article

@article{00da89d21a5a4064b8c66ae0b5782c4f,
title = "Treatment possibilities for psychosis in Parkinson’s disease with an emphasis on the newly approved drug: Pimavanserin",
abstract = "Parkinson’s disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40{\%} of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2A) triggered mechanisms. A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist.",
keywords = "Clozapine, Parkinson’s disease psychosis, Pimavanserin, Quetiapine, Serotonin 2a receptor inverse agonist",
author = "Zs{\'o}fia Majl{\'a}th and Izabella Ob{\'a}l and L. V{\'e}csei",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/1871527315666161006104347",
language = "English",
volume = "16",
pages = "234--243",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Treatment possibilities for psychosis in Parkinson’s disease with an emphasis on the newly approved drug

T2 - Pimavanserin

AU - Majláth, Zsófia

AU - Obál, Izabella

AU - Vécsei, L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Parkinson’s disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2A) triggered mechanisms. A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist.

AB - Parkinson’s disease (PD) is a progressive neurodegenerative disorder with prominent motor and non-motor symptoms. Psychosis develops in over 40% of PD patients and it is one of the most distressing symptoms for patients and caregivers alike. Until recently, atypical antipsychotics, clozapine and quetiapine were used to treat psychotic symptoms, but treatment was associated with substantial concerns for side-effects of clozapine and unfounded efficacy for quetiapine. Extensive research has shown that the antipsychotic effect of these drugs could be attributed to serotonin 2a receptor (5-HT2A) triggered mechanisms. A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD. In this review we primarily focus on psychosis in PD, the current treatment possibilities and the new, emerging therapy, pimavanserin, a selective 5-HT2A inverse agonist.

KW - Clozapine

KW - Parkinson’s disease psychosis

KW - Pimavanserin

KW - Quetiapine

KW - Serotonin 2a receptor inverse agonist

UR - http://www.scopus.com/inward/record.url?scp=85038264582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038264582&partnerID=8YFLogxK

U2 - 10.2174/1871527315666161006104347

DO - 10.2174/1871527315666161006104347

M3 - Review article

C2 - 27719624

AN - SCOPUS:85038264582

VL - 16

SP - 234

EP - 243

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 3

ER -